Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 7/20 | 0.70 |
| ▸ | LIG1 | P18858 | 1/20 | 0.37 |
| ▸ | CXCR3 | P49682 | 5/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 2/20 | 0.34 |
| ▸ | RCOR1 | Q9UKL0 | 2/20 | 0.34 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | MMP9 | P14780 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13201868 | 1.00 | CYP19A1 (0.70) | CYP19A1LIG1CXCR3CHRM1KDM1A | |
| SCHEMBL4759593 | 1.00 | CYP19A1 (0.70) | CYP19A1LIG1CXCR3CHRM1KDM1A | |
| SCHEMBL14520901 | 0.84 | CYP19A1 (0.72) | CYP19A1CXCR3CRBN | |
| SCHEMBL4556388 | 0.84 | CYP19A1 (0.72) | CYP19A1CXCR3CRBN | |
| SCHEMBL10530941 | 0.82 | CYP19A1 (1.00) | CYP19A1 | |
| Cyproximide SCHEMBL121879 | 0.82 | CYP19A1 (0.70) | CYP19A1LIG1CXCR3KDM1ARCOR1 | |
| SCHEMBL10530071 | 0.82 | CYP19A1 (1.00) | CYP19A1 | |
| SCHEMBL22623727 | 0.82 | CYP19A1 (1.00) | CYP19A1 | |
| SCHEMBL1552771 | 0.81 | CYP19A1 (0.69) | CYP19A1CXCR3KDM1AMMP2MMP9 | |
| SCHEMBL2054565 | 0.81 | CYP19A1 (0.69) | CYP19A1CXCR3KDM1AMMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7776904-B2 | Azabicyclo [3.1.0] hexylphenyl derivatives as modulators of dopamine D3 receptors | GLAXO GROUP LIMITED (GB) | 2010-08-17 | — | — | US | disclosed |
| US-20090030062-A1 | AZABICYCLO [3.1.0] HEXYLPHENYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED | 2009-01-29 | — | — | US | disclosed |
| WO-2007022935-A1 | AZABICYCLO [3.1.0] HEXYLPHENYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2007-03-01 | — | — | WO | disclosed |
| US-4435419-A | Method of treating depression using azabicyclohexanes | AMERICAN CYANAMID COMPANY (US) | 1984-03-06 | — | — | US | disclosed |
| US-4231935-A | ANXIOLYTICS AND ANALGESICS | AMERICAN CYANAMID COMPANY (US) | 1980-11-04 | — | — | US | disclosed |
| US-4196120-A | 1,2-BIS(HYDROCARBYLSULFONYLOXY OR HALO METHYL)CYCLOPROPYLBENZENE, OPTICAL ACITIVITY ANALGESICS | AMERICAN CYANAMID COMPANY (US) | 1980-04-01 | — | — | US | disclosed |
| US-4131611-A | ANXIOLYTIC, ANALGESIC | AMERICAN CYANAMID COMPANY (US) | 1978-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030062-A1 | AZABICYCLO [3.1.0] HEXYLPHENYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | DRD3, DRD2, HTR3C | CYP19A1 1550/4885LIG1 4469/4885CXCR3 850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.